Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betadine nasal decolonisation crossover study for persistent nasal Staphylococcus aureus carriage
ACTRN12618001245280Phase 4Withdrawn
- Sponsor
- Orthopaedic Research Institute of Queensland
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of povidone-iodine, mupirocin and saline in staphylococcal carrier state (3 arms), sponsored by Orthopaedic Research Institute of Queensland. Primary endpoint: Change in nasal Staphylococcus aureus concentration after Betadine application at 24 hours. Planned start Jan 2020; status: withdrawn.
02
Drugs
povidone-iodinemupirocinsaline
03
Conditions
staphylococcal carrier state
Beyond the preview
Go deeper on ACTRN12618001245280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001245280.